Abstract
Rats treated chronically with neuroleptics develop vacuous chewing movements (VCMs), similar in some respects to tardive dyskinesia (TD) in man. The VCM syndrome was used as a model of TD to examine the ability of increased neuroleptic doses to produce long-term suppression of dyskinetic movements. The incidence and persistence of the VCM syndrome in individual rats were also assessed to look for affected and unaffected subgroups. Rats were initially treated for 15 weeks with haloperidol decanoate. For the next 21 weeks, half the group received a 50–150% increase in dose while the other half continued to receive the same dose. Animals were also followed during a 28-week withdrawal period. Total VCM ratings showed a skewed distribution, with some rats exhibiting few movements while others developed marked and persistent movements. Increasing doses did not suppress VCMs, nor did they exacerbate movements during the withdrawal period. To the extent that the VCM syndrome models TD, the absence of long-term suppression of the VCM syndrome suggests that, at this dosage range, increasing depot neuroleptic doses may not be a useful long-term strategy for TD suppression.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
APA Task Force on Tardive Dyskinesia, (1992) Tardive dyskinesia — a Task Force Report of the American Psychiatric Association, APA Press, Washington DC
Barnes TR, Wiles DH (1983) Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment. Psychopharmacology 81:359–362
Bartko JJ, Carpenter WT (1976) On the methods and theory of reliability. J Nerv Ment Dis 163:307–317
Bergen JA, Eyland EA, Campbell JA, Jenkings P, Kellehear K, Richards A, Beumont PJV (1989) The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 154:523–528
Curran JP (1973) Management of tardive dyskinesia with thiopropazate. Am J Psychiatry 130:925–927
Doongaji DR, Jeste DV, Jape NM, Sheth AS, Apte JS, Vahia VN, Desai AB, Parkih MD, Rathi LG, Ghandi MH, Parikh RM, Thatte S, Bharadwaj J (1982) Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia. J Clin Psychopharmacol 2:376–379
Egan MF, Hyde TH, Albers GW, Elkashef A, Alexander RC, Reeve A, Blum A, Saenz RE, Wyatt RJ (1992) Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 149:773–777
Farde L, Nordstrom A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiat 49:538–544
Frangos E, Christodoulides H (1975) Clinical observations on the treatment of tardive dyskinesia with haloperidol. Acta Psychiatr Belg 75:19–32
Gale K (1980) Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283:569–570
Gerlach J, Casey DE (1983) Sulpiride in tardive dyskinesia. Acta Psychiatr Scand (suppl) 311[69]:93–101
Gibbons RD, Dorus E, Ostrow DG, Pandey GN, Davis J, Levy D (1984) Mixture distrubutions in psychiatric research. Biol Psychiatry 19:935–961
Glazer WM, Hafez H (1990) A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 3:315–320
Gunne LM, Haggstrom J-E (1983) Reduction in nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology 81:191–194
Gunne, LM, Growden J, Glaeser B (1982) Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology 77:134–139
Gunne LM, Andersson U, Bondesson U, Johansson P (1986) Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 25:897–901
Hess EJ, Norman AB, Creese I (1988) Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on Dland D2 dopamine receptors. J Neurosci 8[7]:2361–2370
Hyde TH, Egan MF, Wing L, Wyatt RJ, Weinberger DR, Kleinman J (1995) Persistent catalepsy is associated with persistent, severe vacuous chewing movements in rats treated with very long-term haloperidol decanoate. Psychopharmacology (in press)
Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10:315–333
Jellinek T, Gardos G, Cole J (1981) Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 138:1567–1571
Jeste DV, Wyatt RJ (1979) In search of treatment for tardive dyskinesia: review of the literature Schizophr Bull 5:251–293
Jeste DV, Wyatt RJ (1982) Therapeutic strategies against tardive dyskinesia: two decades of experience. Arch Gen Psychiatry 39:803–816
Jeste DV, Lohr JB, Clark, K, Wyatt RJ (1988) Pharmacological treatment of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 8:38S-48S
Johansson P, Casey DE, Gunne LM (1986) Dose-dependent increases in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine. Psychopharmacol Bull 22:1017–1019
Jus A, Jus K, Fontaine P (1979) Long term treatment of tardive dyskinesia. J Clin Psychiatry 40:72–77
Kazamatsuri H, Chien C-P, Cole JO (1972) Treatment of tardive dyskinesia II. short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry 27:100–103
Kazamatsuri H, Chien C-P, Cole JO (1973) Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 130:479–483
Klawans HL, Tanner CM, Barr A (1984) The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol 7:153–159
Khot V, Egan MF, Hyde TM, Wyatt RJ (1992) Neuroleptics and classical tardive dyskinesia, In: Lang AE, Weiner WJ (eds) Drug-induced movement disorders. Futura, Mount Kisco, N.Y., pp 121–166
Korsgaard S, Noring U, Gerlack J (1984) Fluperlapine in tardive dyskinesiaand parkinsonism. Psychopharmacology 39:803–816
Leiberman J, Lesser M, Johns C, Pollack S, Saltz B, Kane J (1988a) Pharmacological studies of tardive dyskinesia. J Clin Psychopharmacol 8:57S-63S
Leiberman J, Pollack S, Lesser M, Kane J (1988b) Pharmacological characterization of tardive dyskinesia. J Clin Psychopharmacol 8:254–260
Levy AD, See RE, Levin ED, Ellison GD (1987) Neuroleptic-induced oral movements in rats: methodological issues. Life Sci 41:1499–1506
Mithani S, Atmadja S, Baimbridge KG, Fibiger HC (1987) Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities
Owens DG, Johnstone EC, Frith CD (1982) Spontaneous involuntary disorders of movement. Arch Gen Psychiatry 39:452–461
Piazza PV, Deminiere JM, Le Moal M, Simon H (1989) Factors that predict individual vulnerability to amphetamine self-administration. Science 246, 1511–1513
Rifkin A, Quitikin F, Kane J, Struve F, Klein DF (1978) Are prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 35:483–489
Roxburgh PA (1970) Treatment of persistent phenothiazine-induced oral dyskinesia. Br J Psychiatry 116:277–280
Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology 85:71–79
Rupniak NMJ, Prestwick SA, Horton RW, Jenner P, Marsden CD (1987) Alterations in cerebral glutamic acid decarboxylase and [3H]-flunitrazepam binding during continuous treatment of rats for one year with haloperidol, sulpiride, or clozapine. J Neurol Transm 68:113–125
See R, Ellison G (1990) Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur J Pharmacol 181:175–186
See RE, Aravagiri M, Ellison GD (1989) Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2 but not dopamine D-1 receptors. Life Sci 44:229–236
Singer K, Cheng MN (1971) Thiopropazate hydrochloride in persistent dyskinesia. Br Med J 4:22–25
Smith JS, Kiloh LG (1979) Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia. J Neurol Neurosurg Psychiatry 42:576–579
Steinpreis RE, Baskin P, Salamone JD (1993) Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopalamine. Psychopharmacology 111:99–105
Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N (1990) Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology 102:474–478
Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101:431–447
Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530–532
Waddington JL, Youssef HA, O'Boyle KM, Molloy AG (1986a) A reappraisal of abnormal involuntary movements (tardive dyskinesia) in schizophrenia and other disorders: animal models and alternative hypotheses. In: Winlow W, Markstein T (eds) The neurobiology of dopamine systems. Manchester University Press, Manchester, pp 266–286
Waddington JL, Molloy AG, O'Boyle KM, Youssef HA (1986b) Spontaneous and drug-induced dyskinesias in rodents in relation to ageing and long-term neuroleptic treatment: relationship to tardive dyskinesia. In: Shagass C, Josiassen RC, Bridger W, Weiss K, Stoff D, Simpson G (eds) Biological psychiatry 1985. Elsevier, N.Y., pp 1151–1153
Waddington JL, Molloy AG, O'Boyle KM (1988) Behavioral effects of long-term treatment with further typical neuroleptics and selective D-2 dopamine receptor antagonists in young vs aged animals. In: Sandler M, Dahlstrom A, Belmaker R (eds) Progress in catecholamine research. Part B: Central aspects. Liss, N.Y., pp 43–46
Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A (1987) Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 144: 1148–1153
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Egan, M.F., Wyatt, R.J., Hyde, T.M. et al. Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology 117, 74–81 (1995). https://doi.org/10.1007/BF02245101
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245101